Efficacy and toxicity profile of pegylated liposomal doxorubicin in patients with advanced ovarian cancer

Mayer, Christine; Brucker, Janina; Schuetz, Florian; Domschke, Christoph; Bechstein, Sarah; Heil, Jörg; Golatta, Michael; Wallwiener, Markus; Sohn, Christof; Schneeweiß, Andreas; Rom, Joachim

doi:10.1007/s00404-015-3913-9

Cited by 5 publications

(7 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the PLD monotherapy group, ORR and CBR were 5.0% and 17.5%, respectively. Table 4 presents a comparison of efficacy of PLD monotherapy with different studies [ 11 14 15 ], and the results of this study are poorer than those of other studies. While the average number of previous chemotherapy regimens of other studies was less than 2, the patients in the present study had an average of 3.5 previous chemotherapy regimens; the marked difference in this basic factor appears to have affected the response rate.…”

Section: Discussionmentioning

confidence: 90%

The efficacy and safety of pegylated liposomal doxorubicin monotherapy and combination therapy with carboplatin in Korean patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer: a single-institution experience

et al. 2017

View full text Add to dashboard Cite

ObjectiveThis study aimed to evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) with or without carboplatin in Korean patients with recurrent ovarian cancer (ROC), fallopian tube, or primary peritoneal cancer.MethodsThis retrospective study included 52 patients with ROC, fallopian tube, or primary peritoneal cancer who received PLD (50 mg/m2) between 1st December 2014 and 31th July 2016.ResultsThe mean number of chemotherapy cycles was 3.8 (range, 2 to 9) in the PLD monotherapy group and 7 (range, 2 to 13) in the PLD combined with carboplatin (PLD-C) group. In overall response rates and clinical beneficial rates, PLD monotherapy group shows 5.0% and 17.5%, and PLD-C group shows 33.3% and 75.0%. The mean progression-free survival (PFS) was 5 and 13 months in the PLD monotherapy and PLD-C groups, respectively. At 6 months after treatment initiation, absence of disease progression was confirmed in 6 (15%) and 10 (83.3%) patients in the PLD monotherapy and PLD-C groups. Hematological adverse events (e.g., neutropenia and thrombocytopenia) were more common in the PLD-C group (P<0.001, P=0.004). The incidence of anemia and non-hematological adverse events, including mucositis, hand-foot syndrome, and allergic reactions, was similar in both groups.ConclusionThis study demonstrated the efficacy and safety of PLD monotherapy and PLD-C combination in Korean patients with ROC. This study would be helpful to consider the degree of worry about side effects and treatment expectations after treatment. Further retrospective studies with larger samples are required to confirm the efficacy of PLD monotherapy in Asian patients with platinum-resistant ROC.

show abstract

Section: Discussionmentioning

confidence: 90%

The efficacy and safety of pegylated liposomal doxorubicin monotherapy and combination therapy with carboplatin in Korean patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer: a single-institution experience

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The main toxicities that may occur in AOC patients treated with PLD chemotherapy regimen are nausea, palmar-plantar erythema or hand-foot syndrome, stomatitis, and myelosuppression. [34] Some recent studies showed that the PLD + carboplatin chemotherapy regimen had significantly higher incidence of anemia and thrombocytopenia, and AOC patients receiving PLD + carboplatin chemotherapy regimen had higher incidence of experiencing dose delays than those in the standard treatment arm and may had discontinued treatment because of toxicity or refusal. [35] Accordingly, PLD + carboplatin chemotherapy regimen showed more nonhematologic toxicity for AOC patients.…”

Section: Discussionmentioning

confidence: 99%

Toxicities of different first-line chemotherapy regimens in the treatment of advanced ovarian cancer

Sun

Yang

et al. 2017

Medicine

View full text Add to dashboard Cite

show abstract

“…1,2 Although the most extensive data exist on the development of leukemia in patients with Hodgkin's disease treated with chemotherapy, there are a number of other malignancies for which systemic treatment leads to a second primary cancer at a frequency greater than would be expected in the general population. 2 Pegylated liposomal doxorubicin (PLD) is a liposomal encapsulated form of the chloride salt of doxorubicin [3][4][5] that is currently approved for the treatment of recurrent epithelial ovarian cancer, Acquired immunodeficiency syndromerelated Kaposi's sarcoma, desmoid tumor, and metastatic breast cancer. 6,7 PLD has good tolerability demonstrated in both prospective and retrospective studies and a favorable safety profile compared to conventional doxorubicin, which is associated with cardiotoxicity.…”

Section: Introductionmentioning

confidence: 99%

“…6,7 PLD has good tolerability demonstrated in both prospective and retrospective studies and a favorable safety profile compared to conventional doxorubicin, which is associated with cardiotoxicity. [4][5][6]8 The most common treatment-related adverse events associated with PLD include palmar-plantar erythrodysesthesia and stomatitis. 4,6 The development of secondary malignancies, specifically squamous cell carcinoma (SCC) of the oral cavity, is recognized in patients treated with long-term PLD for Kaposi's sarcoma, desmoid tumor, recurrent uterine papillary serous carcinoma, and recurrent high-grade serous carcinoma, the majority of which are of ovarian origin.…”

Section: Introductionmentioning

confidence: 99%

“…[4][5][6]8 The most common treatment-related adverse events associated with PLD include palmar-plantar erythrodysesthesia and stomatitis. 4,6 The development of secondary malignancies, specifically squamous cell carcinoma (SCC) of the oral cavity, is recognized in patients treated with long-term PLD for Kaposi's sarcoma, desmoid tumor, recurrent uterine papillary serous carcinoma, and recurrent high-grade serous carcinoma, the majority of which are of ovarian origin. 5,[8][9][10][11] These findings are reported in the gynecologic and oncology literature through case reports, letters to the editor, and retrospective reviews, but no such report has been described in the otolaryngology literature.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Oral Squamous Cell Carcinoma as a Complication of Treatment for Recurrent High‐Grade Serous Cancer

et al. 2019

View full text Add to dashboard Cite

Objectives/Hypothesis: Advances in cancer treatment have increased survival for many patients, prompting a need for greater recognition of the long-term complications of treatment. Chemotherapy agents have the potential to induce carcinogenesis and can increase the risk of secondary malignancy. Pegylated liposomal doxorubicin (PLD) used for maintenance treatment of recurrent high-grade serous cancers has been associated with the development of oral cavity squamous cell carcinoma (SCC). Study Design: Retrospective review. Methods: Cases of oral cavity SCC in patients with recurrent high-grade serous cancer treated with PLD between 1997 and 2017 at a single institution were reviewed. Results: Eight of 16 patients treated with PLD developed oral cavity SCC. The duration of PLD use ranged from 1.3 to 15 years (mean = 5.8 years) and cumulative dose ranged from 405 to 3,000 mg/m 2 (mean = 1,542 mg/m 2). Seven patients tested positive for BRCA mutations (four BRCA 1+, three BRCA 2+). No patients had a history of alcohol or tobacco use. All had early-stage oral cavity disease; five were T1N0, two were T2N0, and one had carcinoma in situ. All patients underwent surgery, and two received adjuvant radiation. Four developed locoregional recurrence requiring additional treatment. Of these, one patient died from complications of oral SCC, one developed recurrent ovarian cancer, and two had no evidence of disease of the oral cavity or ovarian cancer at the last follow-up. Conclusions: Long-term PLD therapy may be associated with the development of oral cavity SCC. A high index of suspicion and routine head and neck examination should be included in follow-up for exposed patients.

show abstract

Efficacy and toxicity profile of pegylated liposomal doxorubicin in patients with advanced ovarian cancer

Abstract: In conclusion, this retrospective study showed the efficacy and low toxicity of pegylated liposomal doxorubicin in patients with advanced EOC. Further observations are needed to confirm these preliminary experiences on a larger number of patients.

Cited by 5 publications

References 30 publications

The efficacy and safety of pegylated liposomal doxorubicin monotherapy and combination therapy with carboplatin in Korean patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer: a single-institution experience

The efficacy and safety of pegylated liposomal doxorubicin monotherapy and combination therapy with carboplatin in Korean patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer: a single-institution experience

Toxicities of different first-line chemotherapy regimens in the treatment of advanced ovarian cancer

Oral Squamous Cell Carcinoma as a Complication of Treatment for Recurrent High‐Grade Serous Cancer

Contact Info

Product

Resources

About